J Cancer
2019; 10(9):2063-2073.
doi:10.7150/jca.29327 This issueCite
Research Paper
Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells
Fangling Huang1,2, Xujun Liang1, Xiaoli Min1, Ye Zhang1, Guoqiang Wang1, Zhengrong Peng2, Fang Peng1, Maoyu Li1, Lin Chen1, Yongheng Chen1✉
1. Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, XiangYa Hospital, Central South University, Changsha, Hunan 410008, China 2. Department of Hyperbaric Oxygen, Xiangya Hospital, Central South University, Changsha 410008, China
✉ Corresponding author: Prof. Yongheng Chen, Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, XiangYa Hospital, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, P.R. China. E-mail:yonghenccom.
Citation:
Huang F, Liang X, Min X, Zhang Y, Wang G, Peng Z, Peng F, Li M, Chen L, Chen Y. Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells. J Cancer 2019; 10(9):2063-2073. doi:10.7150/jca.29327. https://www.jcancer.org/v10p2063.htm
Ionizing radiation (IR) is the central component of the therapeutic scheme for nasopharyngeal carcinoma (NPC) at present. Previous studies show that inhibition of epidermal growth factor receptor (EGFR) enhances the radiosensitivity of NPC; however the effects of EGFR-targeted agents are limited. In this study, we observed that simultaneously inhibition of EGFR and HER2 by afatinib could augment the radiosensitivity of NPC cells; this approach has an advantage over erlotinib-mediated inhibition of EGFR alone. The afatinib-induced augmentation of NPC cell radiosensitivity was associated with increases in apoptosis and accumulation of DNA damage that were induced by radiation. In addition, the crosstalk between radiation-induced activities and EGFR-, and HER2-related downstream pathways may contribute to the enhancement of radiosensitivity. Our findings indicate the potential of repositioning afatinib or other ERBB-family-targeted agents for improving radiation response in NPC cells.
Huang, F., Liang, X., Min, X., Zhang, Y., Wang, G., Peng, Z., Peng, F., Li, M., Chen, L., Chen, Y. (2019). Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells. Journal of Cancer, 10(9), 2063-2073. https://doi.org/10.7150/jca.29327.
ACS
Huang, F.; Liang, X.; Min, X.; Zhang, Y.; Wang, G.; Peng, Z.; Peng, F.; Li, M.; Chen, L.; Chen, Y. Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells. J. Cancer 2019, 10 (9), 2063-2073. DOI: 10.7150/jca.29327.
NLM
Huang F, Liang X, Min X, Zhang Y, Wang G, Peng Z, Peng F, Li M, Chen L, Chen Y. Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells. J Cancer 2019; 10(9):2063-2073. doi:10.7150/jca.29327. https://www.jcancer.org/v10p2063.htm
CSE
Huang F, Liang X, Min X, Zhang Y, Wang G, Peng Z, Peng F, Li M, Chen L, Chen Y. 2019. Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells. J Cancer. 10(9):2063-2073.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Global reach, higher impact
